Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently announced, Fiserv, Inc. (FISV - Analyst Report) extended its ties with Carleton, Inc. The company decided to ameliorate its Common Origination Platform with Carleton’s SmartCales financial tool.
The SmartCales financial software is a lending calculation software which would allow mortgage, business and consumer lenders at every hierarchy to make calculations easily from anywhere to better cater to their customers’ risk management solutions. The calculation files shall be integrated pervasively with the Common Origination Platform and shall be consistently maintained and deployed by Carleton throughout the U.S.
Previously, the SmartCalcs software had been used only in the Automotive Loan Origination System. This extension made with Carleton shall enhance the Common Origination Platform of Fiserv leading to value maximization for its customers. Furthermore, the bond with Carleton since 2007, shall also strengthen immensely for the company through this venture.
Fiserv announced the financial results for its final quarter of 2011 on February 2, 2012. The company posted an astounding performance in its Financial and Institution Services segment with revenues rising almost 7% to $540 million in the quarter. Elevated high-margin sales and improved cost efficiencies also allowed the segment to report a rise in operating margin to 33% from 31.8% in the previous year period.
The company currently projects adjusted revenues to grow 4% - 6% in 2012. Even though major growth drivers are expected to act from mid-2012, the current advances made by Fiserv puts it in quite a favorable position to battle ongoing headwinds.
Developments, especially on the positive side, are not singularly peculiar to Fiserv. Not long ago, Heartland Payment Systems (HPY - Snapshot Report) announced that its Mobuyle mobile acceptance solution shall now be integrated with Apple, Inc. (AAPL - Analyst Report) products, namely its iOS mobile phones. Other ominous competitors prevalent in the industry are Equifax Inc. (EFX - Analyst Report) and Fidelity National Information Services, Inc. (FIS - Analyst Report).
At present we have a Neutral recommendation on Fiserv. The stock currently carries a Zacks #2 Rank, which translates into a short-term rating of Buy.
Get the full Analyst Report on FIS - FREE
Get the full Analyst Report on FISV - FREE
Get the full Analyst Report on AAPL - FREE
Get the full Analyst Report on EFX - FREE
Get the full Snapshot Report on HPY - FREE